Progen-Avexa deal goes bung
Tuesday, 10 March, 2009
Progen has ended its bid for a merger with Avexa after shareholders overwhelmingly rejected the deal.
It is understood that the vast majority of proxy votes opposed the deal, which would have seen the Brisbane oncology company, which has rich cash reserves but a dry pipeline after the cancellation of its Phase III liver cancer trial in July last year, join with Avexa.
Avexa is in Phase III trials of a nucleoside reverse transcriptase inhibitor for drug-resistant HIV.
Melbourne’s Cytopia, also an oncology company and a shareholder in the company, has made a counter-bid and urged shareholders to reject the deal.
A Progen general meeting was to be held tomorrow but has now been cancelled. Shareholders will vote on the Cytopia offer on March 27.
A statement from Cytopia is expected shortly.
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
